TIANMA Group
TIANMA (TM) is a diversified group listed on the Chinese Stock Market with over two decades of experience delivering customized services in the chemical sector. Headquartered in Nanjing, China, the group focuses on pharmaceutical intermediates, agrochemicals, and nutrition-related products, complemented by activities in financial investments and real estate. The company emphasizes its role as a professional solutions provider for chemical contract manufacturing, supported by an integrated approach designed to meet the evolving demands of clients in highly regulated environments.
Key capabilities highlighted by the group include cGMP and non-GMP facilities, indicating a flexible manufacturing footprint that accommodates both compliant pharmaceutical processes and broader chemical production. TIANMA undertakes contract manufacturing for advanced intermediates in Suzhou, as well as phosgene derivatives in Shandong and NaCN derivatives in Nantong, illustrating a geographically distributed production network that leverages regional strengths across China.
A dedicated project management structure is described, with an assigned project manager supervising each engagement to ensure accountability and client alignment. The company also features an independent R&D center to support technology development, underscoring a commitment to process innovation and optimization.
The firm emphasizes a fast response scheme and a sophisticated quality system, reflecting a focus on operational reliability and compliance. In addition, TIANMA highlights its adherence to an international EHS framework, which supports safe and sustainable practices across its activities. The portfolio targets advanced drug intermediates and fine chemicals, with capabilities spanning pilot-scale operations through to commercial quantity production, and the ability to execute specialized chemical reactions.
Overall, TIANMA Group presents itself as a vertically integrated chemical contract manufacturing partner with emphasis on customized project execution, strong quality controls, and a scalable pathway from pilot to commercial production.